Pantherna Therapeutics GmbH and ARCALIS, Inc. enter research collaboration to expand novel LNP solutions for future mRNA therapeutics

Pantherna Therapeutics, a biotech company enabling innovative mRNA therapies with tissue/-cell-selective LNP formulations, has entered a research collaboration with ARCALIS, Inc., a CDMO with expertise in GMP manufacturing of mRNA-LNP products such as the approved self-amplifying mRNA vaccine against COVID-19. As part of this collaboration, Pantherna grants ARCALIS access to its proprietary PTX_LNP technology to explore and evaluate selected LNP formulations. The aim is to assess their potential for future integration into ARCALIS’s service portfolio, enabling a broader and more tailored range of mRNA-LNP solutions for biotech/ pharma partners.

This joint effort reflects a shared commitment of both parties to complementing each other’s strengths, fostering innovation, and co-developing flexible delivery technologies that support the evolving needs of RNA-based therapeutic development for the European and Asian market.